69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 69,724 shares of the company’s stock, valued at approximately $2,948,000. Raymond James Financial Inc. owned approximately 0.11% of Vera Therapeutics at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Holocene Advisors LP lifted its holdings in Vera Therapeutics by 8.8% during the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock worth $86,390,000 after purchasing an additional 158,451 shares during the last quarter. Geode Capital Management LLC boosted its position in Vera Therapeutics by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock worth $44,415,000 after buying an additional 20,223 shares during the period. Jennison Associates LLC increased its holdings in Vera Therapeutics by 82.0% in the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock valued at $34,418,000 after purchasing an additional 366,763 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Vera Therapeutics by 19.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 430,665 shares of the company’s stock valued at $18,213,000 after acquiring an additional 68,860 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock valued at $18,830,000 after acquiring an additional 124,197 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on VERA shares. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a report on Tuesday, March 4th. Guggenheim lifted their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target on the stock. Finally, Wolfe Research assumed coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $64.67.

Insider Activity

In other news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Stock Up 0.4 %

VERA stock opened at $26.63 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -10.20 and a beta of 1.17. Vera Therapeutics, Inc. has a fifty-two week low of $25.55 and a fifty-two week high of $51.61. The stock has a fifty day moving average of $30.93 and a 200-day moving average of $38.87.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. As a group, equities research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.